表紙
市場調查報告書

濕疹治療藥的全球市場:2020年∼2024年

Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 920023
出版日期 內容資訊 英文 152 Pages
訂單完成後即時交付
價格
Back to Top
濕疹治療藥的全球市場:2020年∼2024年 Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月11日內容資訊: 英文 152 Pages
簡介

全球濕疹治療藥市場上,異位性皮膚炎的高得病率,強力的開發平台環境,主要產品的銷售等成為成長促進因素,在預測期間內預計將以9%以上的年複合成長率擴大。但,皮質類固醇相關的副作用,供應商間的激烈競爭,及嚴格法規指南等要素,可能妨礙在預測期間內濕疹治療藥產業的成長。

本報告提供全球濕疹治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析
  • 價值鏈分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 客戶形勢

第7章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第8章 市場區隔:各症狀

  • 市場區隔:各症狀
  • 各症狀比較:市場規模及預測(2019年∼2024年)
  • 異位性皮膚炎
  • 接觸皮膚炎
  • 其他
  • 市場機會:各症狀

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 事業策略
  • 地緣政治學的不確定性
  • 醫療費的增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40707

About this market

Technavio's eczema therapeutics market analysis considers sales from atopic dermatitis, contact dermatitis, and other indication. Our study also finds the sales of eczema therapeutics in Asia, Europe, North America, and ROW. In 2019, the atopic dermatitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of chronic, highly pruritic inflammatory skin disorders will play a significant role in the atopic dermatitis segment to maintain its market position. Also, our global eczema therapeutics market report looks at factors such as the high prevalence of atopic dermatitis, strong pipeline landscapes, and major product launches. However, side effects associated with corticosteroids, intense competition among vendors, and stringent regulatory guidelines may hamper the growth of the eczema therapeutics industry over the forecast period.

Overview

High prevalence of atopic dermatitis

Exposure to skin irritants including soaps or cleaners and allergens such as pet dander, pollen, or peanuts can lead to eczema. It is also caused by infections, dry skin, and stress. Atopic dermatitis is one of the most prevalent forms of eczema which requires multiple visits to dermatologists and numerous medications for treatment. China, India, and Japan are the three major revenue contributors to the market as these regions of Asia constitute a huge patient pool and consequently exhibit a high demand for eczema therapeutics. Thus, the high prevalence of atopic dermatitis will lead to the expansion of the global eczema therapeutics market at a CAGR of over 9% during the forecast period.

Increasing healthcare expenditure

Healthcare expenditure is increasing owing to the growing prevalence of allergic and inflammatory skin diseases in people globally. For the treatment of highly prevalent diseases such as atopic dermatitis, dermatologists are prescribing many OTC drugs and generic medications such as corticosteroids, antihistamines, and topical antiseptics due to the high number of clinical visits. The market is also witnessing an increased adoption of expensive, novel, and branded drugs for a more effective treatment. Moreover, the growing awareness of the need for early diagnosis of skin diseases, as well as the risks of negligence in seeking timely medical help, is making people increasingly health-conscious, which, in turn, is organically increasing the healthcare expenditure.

For the detailed list of factors that will drive the global eczema therapeutics market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global eczema therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics manufacturers, that include AbbVie Inc., Alliance Pharma Plc, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc., LEO Pharma AS, Mylan NV, Pfizer Inc., and Sanofi.

Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 08: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Atopic dermatitis - Market size and forecast 2019-2024
  • Contact dermatitis - Market size and forecast 2019-2024
  • Other indication - Market size and forecast 2019-2024
  • Market opportunity by indication

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Business strategies
  • Geopolitical uncertainties
  • Increasing healthcare expenditure

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key Offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Customer landscape
  • Exhibit 19: Market share by geography 2019-2024 (%)
  • Exhibit 20: Geographic comparison
  • Exhibit 21: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 22: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 23: Top 3 countries in North America
  • Exhibit 24: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 25: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 26: Top 3 countries in Europe
  • Exhibit 27: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 28: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 29: Top 3 countries in Asia
  • Exhibit 30: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 31: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Top 3 countries in ROW
  • Exhibit 33: Key leading countries
  • Exhibit 34: Market opportunity
  • Exhibit 35: Indication - Market share 2019-2024 (%)
  • Exhibit 36: Comparison by indication
  • Exhibit 37: Atopic dermatitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: Atopic dermatitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Contact dermatitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: Contact dermatitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Other indication - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 42: Other indication - Year-over-year growth 2020-2024 (%)
  • Exhibit 43: Market opportunity by indication
  • Exhibit 44: Product launch details
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Business strategies
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AbbVie Inc. - Vendor overview
  • Exhibit 53: AbbVie Inc. - Business segments
  • Exhibit 54: AbbVie Inc. - Organizational developments
  • Exhibit 55: AbbVie Inc. - Geographic focus
  • Exhibit 56: AbbVie Inc. - Key offerings
  • Exhibit 57: AbbVie Inc. - Key customers
  • Exhibit 58: Alliance Pharma Plc - Vendor overview
  • Exhibit 59: Alliance Pharma Plc - Business segments
  • Exhibit 60: Alliance Pharma Plc - Organizational developments
  • Exhibit 61: Alliance Pharma Plc - Geographic focus
  • Exhibit 62: Alliance Pharma Plc - Segment focus
  • Exhibit 63: Alliance Pharma Plc - Key offerings
  • Exhibit 64: Alliance Pharma Plc - Key customers
  • Exhibit 65: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 66: Bausch Health Companies Inc. - Business segments
  • Exhibit 67: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 68: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 69: Bausch Health Companies Inc. - Segment focus
  • Exhibit 70: Bausch Health Companies Inc. - Key offerings
  • Exhibit 71: Bausch Health Companies Inc. - Key customers
  • Exhibit 72: Bayer AG - Vendor overview
  • Exhibit 73: Bayer AG - Business segments
  • Exhibit 74: Bayer AG - Organizational developments
  • Exhibit 75: Bayer AG - Geographic focus
  • Exhibit 76: Bayer AG - Segment focus
  • Exhibit 77: Bayer AG - Key offerings
  • Exhibit 78: Bayer AG - Key customers
  • Exhibit 79: Eli Lilly and Co. - Vendor overview
  • Exhibit 80: Eli Lilly and Co. - Business segments
  • Exhibit 81: Eli Lilly and Co. - Organizational developments
  • Exhibit 82: Eli Lilly and Co. - Geographic focus
  • Exhibit 83: Eli Lilly and Co. - Segment focus
  • Exhibit 84: Eli Lilly and Co. - Key offerings
  • Exhibit 85: Eli Lilly and Co. - Key customers
  • Exhibit 86: Encore Dermatology Inc. - Vendor overview
  • Exhibit 87: Encore Dermatology Inc. - Product segments
  • Exhibit 88: Encore Dermatology Inc. - Organizational developments
  • Exhibit 89: Encore Dermatology Inc. - Key offerings
  • Exhibit 90: Encore Dermatology Inc. - Key customers
  • Exhibit 91: LEO Pharma AS - Vendor overview
  • Exhibit 92: LEO Pharma AS - Product segments
  • Exhibit 93: LEO Pharma AS - Organizational developments
  • Exhibit 94: LEO Pharma AS - Key offerings
  • Exhibit 95: LEO Pharma AS - Key customers
  • Exhibit 96: Mylan NV - Vendor overview
  • Exhibit 97: Mylan NV - Product segments
  • Exhibit 98: Mylan NV - Organizational developments
  • Exhibit 99: Mylan NV - Geographic focus
  • Exhibit 100: Mylan NV - Segment focus
  • Exhibit 101: Mylan NV - Key offerings
  • Exhibit 102: Mylan NV - Key customers
  • Exhibit 103: Pfizer Inc. - Vendor overview
  • Exhibit 104: Pfizer Inc. - Business segments
  • Exhibit 105: Pfizer Inc. - Organizational developments
  • Exhibit 106: Pfizer Inc. - Geographic focus
  • Exhibit 107: Pfizer Inc. - Segment focus
  • Exhibit 108: Pfizer Inc. - Key offerings
  • Exhibit 109: Pfizer Inc. - Key customers
  • Exhibit 110: Sanofi - Vendor overview
  • Exhibit 111: Sanofi - Business segments
  • Exhibit 112: Sanofi - Organizational developments
  • Exhibit 113: Sanofi - Geographic focus
  • Exhibit 114: Sanofi - Segment focus
  • Exhibit 115: Sanofi - Key offerings
  • Exhibit 116: Sanofi - Key customers
  • Exhibit 117: Validation techniques employed for market sizing
  • Exhibit 118: Definition of market positioning of vendors
Back to Top